Schein P S, Lavin P T, Moertel C G, Frytak S, Hahn R G, O'Connell M J, Reitemeier R J, Rubin J, Schutt A J, Weiland L H, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Redlhammer D, Silverman M, Troner M, Douglass H O, Milliron S, Lokich J, Brooks J, Chaffe J, Like A, Zamcheck N, Ramming K, Bateman J, Spiro H, Livstone E, Knowlton A
Cancer. 1978 Jul;42(1):19-22. doi: 10.1002/1097-0142(197807)42:1<19::aid-cncr2820420103>3.0.co;2-4.
Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used to objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy.
66例晚期胰腺癌患者被随机分组，接受阿霉素、甲氨蝶呤或放线菌素D单药化疗，采用常规剂量、给药途径和给药方案。所有患者均有可测量病灶，用于客观评估疗效。对于阿霉素，25例患者中有2例（8%）出现部分缓解（15例既往未治疗患者中有2例（13%））。接受甲氨蝶呤治疗的25例患者中有1例有反应，接受放线菌素D治疗的28例患者中有1例有反应。对于研究入组前未接受化疗的患者，缓解持续时间为43 - 64天。接受阿霉素作为初始治疗的患者中位生存期为12周，而接受甲氨蝶呤治疗的患者为8周，接受放线菌素D治疗的患者为6周。
